Targeted conventional therapies involve amino‐salicylates (5‐ASA), azathioprine, corticosteroids, as well as monoclonal antibodies and inhibitors of TNF that could slow down IBD progress, which ranges from mild to severe [13, 14]. Here, TNF is linked to inflammatory bowel disease.